KLTO
Klotho Neurosciences, Inc.NASDAQHealthcare$0.38-7.10%ClosedMarket Cap: $20.1M
As of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
—
P/S
—
EV/EBITDA
—
DCF Value
$-0.01
FCF Yield
—
Div Yield
—
Margins & Returns
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROA
—
ROIC
—
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-2.9M | $-0.05 |
| Q2 2025 | $0.00 | $-4.1M | $-0.12 |
| Q1 2025 | $0.00 | $-2.2M | $-0.08 |
| Q4 2024 | $0.00 | $-2.1M | $-0.08 |
Trading Activity
Insider Trades
View AllLeBlanc Jeffofficer: Chief Financial Officer
SellFri Mar 06
El-Dada Riad Husseindirector
SellFri Mar 06
ZENTMAN SAMUEL Mdirector
SellFri Mar 06
Hirschman Shalomdirector
SellFri Mar 06
McGarity Jondirector
SellFri Mar 06
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.23
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.